Latest SILVERARC CAPITAL MANAGEMENT, LLC Stock Portfolio
SILVERARC CAPITAL MANAGEMENT, LLC Performance:
2024 Q3: 8.05%YTD: 23.82%2023: 13.25%
Performance for 2024 Q3 is 8.05%, and YTD is 23.82%, and 2023 is 13.25%.
About SILVERARC CAPITAL MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings
SILVERARC CAPITAL MANAGEMENT, LLC is a hedge fund based in BOSTON, MA. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $441.6 Millions. In it's latest 13F Holdings report, SILVERARC CAPITAL MANAGEMENT, LLC reported an equity portfolio of $445.3 Millions as of 30 Sep, 2024.
The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are NUVL, MRUS, INSM. The fund has invested 8.5% of it's portfolio in NUVALENT INC and 7.1% of portfolio in MERUS N V.
The fund managers got completely rid off MORPHIC HLDG INC (MORF), MIRUM PHARMACEUTICALS INC (MIRM) and JASPER THERAPEUTICS INC (JSPR) stocks. They significantly reduced their stock positions in VYNE THERAPEUTICS INC (VYNE), CELLDEX THERAPEUTICS INC NEW (CLDX) and KODIAK SCIENCES INC (KOD). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in CENTESSA PHARMACEUTICALS PLC (CNTA), PROTAGONIST THERAPEUTICS INC (PTGX) and BIONTECH SE. The fund showed a lot of confidence in some stocks as they added substantially to VAXCYTE INC (PCVX), INSMED INC (INSM) and BIODESIX INC (BDSX).
The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are NUVL, MRUS, INSM. The fund has invested 8.5% of it's portfolio in NUVALENT INC and 7.1% of portfolio in MERUS N V.
The fund managers got completely rid off MORPHIC HLDG INC (MORF), MIRUM PHARMACEUTICALS INC (MIRM) and JASPER THERAPEUTICS INC (JSPR) stocks. They significantly reduced their stock positions in VYNE THERAPEUTICS INC (VYNE), CELLDEX THERAPEUTICS INC NEW (CLDX) and KODIAK SCIENCES INC (KOD). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in CENTESSA PHARMACEUTICALS PLC (CNTA), PROTAGONIST THERAPEUTICS INC (PTGX) and BIONTECH SE. The fund showed a lot of confidence in some stocks as they added substantially to VAXCYTE INC (PCVX), INSMED INC (INSM) and BIODESIX INC (BDSX).
SILVERARC CAPITAL MANAGEMENT, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that SILVERARC CAPITAL MANAGEMENT, LLC made a return of 8.05% in the last quarter. In trailing 12 months, it's portfolio return was 50.22%.
New Buys
| Ticker | $ Bought |
|---|---|
| centessa pharmaceuticals plc | 11,906,000 |
| protagonist therapeutics inc | 6,599,560 |
| biontech se | 3,097,880 |
| relay therapeutics inc | 2,968,230 |
| zevra therapeutics inc | 2,429,000 |
| bioage labs inc | 2,080,000 |
| unicycive therapeutics inc | 1,631,600 |
| xencor inc | 1,518,450 |
New stocks bought by SILVERARC CAPITAL MANAGEMENT, LLC
Additions
| Ticker | % Inc. |
|---|---|
| vaxcyte inc | 2,320 |
| insmed inc | 148 |
| biodesix inc | 96.86 |
| geron corp | 80.29 |
| veracyte inc | 66.72 |
| modular med inc | 60.00 |
| rhythm pharmaceuticals inc | 38.4 |
| wave life sciences ltd | 26.66 |
Additions to existing portfolio by SILVERARC CAPITAL MANAGEMENT, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| vyne therapeutics inc | -83.57 |
| celldex therapeutics inc new | -61.32 |
| kodiak sciences inc | -52.92 |
| trevi therapeutics inc | -42.84 |
| mersana therapeutics inc | -36.58 |
| perspective therapeutics inc | -35.39 |
| c4 therapeutics inc | -20.44 |
| nuvalent inc | -20.24 |
SILVERARC CAPITAL MANAGEMENT, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| evogene ltd | -2,003,060 |
| morphic hldg inc | -16,568,400 |
| fulcrum therapeutics inc | -2,470,300 |
| macrogenics inc | -1,572,500 |
| zura bio ltd | -1,149,760 |
| engene holdings inc | -2,488,020 |
| stoke therapeutics inc | -1,911,910 |
| jasper therapeutics inc | -2,494,550 |
SILVERARC CAPITAL MANAGEMENT, LLC got rid off the above stocks
Sector Distribution
SILVERARC CAPITAL MANAGEMENT, LLC has about 89.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 89.9 |
| Others | 10.1 |
Market Cap. Distribution
SILVERARC CAPITAL MANAGEMENT, LLC has about 10.3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 37.2 |
| MID-CAP | 34.7 |
| LARGE-CAP | 10.3 |
| UNALLOCATED | 10 |
| MICRO-CAP | 5.1 |
| NANO-CAP | 2.8 |
Stocks belong to which Index?
About 64.2% of the stocks held by SILVERARC CAPITAL MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 64.2 |
| Others | 34.9 |
SILVERARC CAPITAL MANAGEMENT, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC
SILVERARC CAPITAL MANAGEMENT, LLC has 68 stocks in it's portfolio. About 47% of the portfolio is in top 10 stocks. MRUS proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for SILVERARC CAPITAL MANAGEMENT, LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADCT | adc therapeutics sa | 1.27 | 1,795,080 | 5,654,500 | added | 1.49 | ||
| AKRO | akero therapeutics inc | 4.12 | 639,840 | 18,357,000 | added | 2.36 | ||
| ALGS | aligos therapeutics inc | 0.05 | 26,219 | 227,057 | new | |||
| ALGS | aligos therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 2.21 | 35,774 | 9,838,920 | reduced | -0.63 | ||
| APLT | applied therapeutics inc | 0.19 | 100,000 | 850,000 | new | |||
| AZYO | elutia inc | 1.41 | 1,645,810 | 6,270,530 | added | 2.63 | ||
| BDSX | biodesix inc | 1.42 | 3,561,090 | 6,338,750 | added | 96.86 | ||
| BDTX | black diamond therapeutics i | 0.10 | 100,000 | 435,000 | new | |||
| BIIB | biogen inc | 0.87 | 19,940 | 3,865,170 | added | 2.97 | ||
| CCCC | c4 therapeutics inc | 1.47 | 1,147,890 | 6,542,980 | reduced | -20.44 | ||
| CERS | cerus corp | 0.58 | 1,495,330 | 2,601,870 | added | 2.02 | ||
| CLDX | celldex therapeutics inc new | 1.11 | 145,000 | 4,928,550 | reduced | -61.32 | ||
| CNTA | centessa pharmaceuticals plc | 2.67 | 744,592 | 11,906,000 | new | |||
| COGT | cogent biosciences inc | 2.96 | 1,221,360 | 13,190,700 | added | 1.26 | ||
| ERAS | erasca inc | 4.26 | 6,946,490 | 18,963,900 | reduced | -11.14 | ||
| ETNB | 89bio inc | 0.15 | 92,298 | 683,005 | unchanged | 0.00 | ||
| EYPT | eyepoint pharmaceuticals inc | 0.18 | 100,000 | 799,000 | unchanged | 0.00 | ||
| FULC | fulcrum therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| GERN | geron corp | 1.84 | 1,801,560 | 8,179,090 | added | 80.29 | ||